Ozempic Price Crash 😳 ₹90,000 to ₹1,290 Explained

A drug that used to cost ₹90,000… is now available for just ₹1,290 😳 What changed? On March 20, 2026, the patent for semaglutide — the key molecule behind Ozempic — expired in India. And within weeks, Indian pharma companies moved fast. Natco Pharma, Eris Lifesciences, Glenmark, Zydus, Sun Pharma, Dr. Reddy’s — multiple players launched their own versions aggressively at a fraction of the original price. This is the classic Indian pharma playbook: When patents expire, competition explodes. But here’s the smarter investor question: Who really wins from this trend? Because beyond pharma companies, there are entire ecosystems benefiting — from medical device manufacturers (injection systems) to diagnostics and doctor-led distribution networks. This is not just a price crash. This is a new market being created. If you want a full breakdown of the winners in this space, comment “Breakdown”.